Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Week in Review

Summaries of each week's events in China biotech are provided free to all readers.  A weekly email newsletter providing direct links to these articles is also available - click here for free email newsletter...

Week in Review: Fosun's Gland Pharma Approved for $814 Million IPO in India

Week in Review: Curon Bio Acquires Rights to Lymphoma Drug in $150 Million Deal

Week in Review: $1.5 Billion Total in Week's China Deals

Week in Review: Zai Lab Completes Second Listing with $761 Million HK IPO

Week in Review: Illumina Pays $8 Billion to Acquire GRAIL, an Early-Stage Cancer Testing Company

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

ChinaBio® Events

ChinaBio Partnering Forum 2020

Content Availbalble Until Dec. 21, 2020